OmniAb (NASDAQ:OABIW – Get Free Report) will likely be announcing its resultson Thursday, May 7th. Analysts expect the company to announce earnings of ($0.1043) per share and revenue of $5.60 million for the quarter.
OmniAb Stock Performance
Shares of NASDAQ OABIW opened at $0.11 on Tuesday. The stock’s 50 day moving average price is $0.09 and its two-hundred day moving average price is $0.11. OmniAb has a 52-week low of $0.08 and a 52-week high of $0.30.
About OmniAb
OmniAb, Inc is a clinical?stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high?throughput screening and bioinformatics, OmniAb aims to streamline the development of next?generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single?cell screening capabilities.
See Also
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
